Price negotiations begin for breast cancer combo drugs

25 March 2020 - Drug makers and the government will start talks this week to negotiate prices of breast cancer ...

Read more →

Gastric cancer drug Liporaxel nears getting insurance benefit

6 March 2020 - Daehwa Pharmaceutical’s Liporaxel (paclitaxel), a treatment for advanced, metastatic and local recurrent gastric cancer, has neared ...

Read more →

Regulator OKs Pfizer's Vizimpro as first-line treatment of mutated lung cancer

20 February 2020 - Pfizer Korea said Thursday that the Ministry of Food and Drug Safety has approved Vizimpro (dacomitinib) ...

Read more →

Interferon, Kaletra to get insurance benefit for new coronavirus treatment

4 February 2020 - The government said it would allow health insurance benefits for patients who received interferon or combo ...

Read more →

‘Dupixent revolutionary atopic dermatitis drug to end lack of fundamental treatment’

29 January 2020 - Sanofi Genzyme exec stresses development of accurate pain index for patients. ...

Read more →

Reimbursement for Repatha to expand treatment options for ASCVD patients

22 January 2020 - Amgen is set to expand treatment options for atherosclerotic cardiovascular disease patients with Repatha, a high-cholesterol treatment, ...

Read more →

Regulatory agency expands cooperation with European counterparts

18 december 2019 - The Ministry of Food and Drug Safety said that it has signed multiple agreements with its ...

Read more →

Drug makers strongly oppose post-approval evaluation

4 December 2019 - The pharmaceutical industry adamantly criticised the government’s plan to evaluate expensive anti-cancer therapies and orphan drugs, ...

Read more →

Value assessment on anti-cancer drugs hotly discussed

24 October 2019 - Experts are raising the need to establish tools to calculate the value of new anticancer medicines ...

Read more →

Sanofi to cover part of Dupixent cost for atopic dermatitis patients

11 October 2019 - Sanofi said it would run a program to support part of the cost of Dupixent, a ...

Read more →

CDK4/6 inhibitor+fulvestrant combo nears getting benefit

2 October 2019 - The combination therapy of cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor and fulvestrant for advanced or metastatic ...

Read more →

'Xtandi emerges as convenient treatment option for prostate cancer patients'

25 September 2019 - Astellas Korea is strengthening its position in the local prostate cancer market with Xtandi, a hormone therapy ...

Read more →

Lenvima to get benefit as first-line treatment of hepatocellular carcinoma

16 September 2019 - Lenvima (lenvatinib), a new liver cancer drug that arrived in a decade after Nexavar (sorafenib), is to ...

Read more →

Pharmacists demand audit over Gliatilin’s insurance benefit

27 August 2019 - A pharmacists’ group demanded an audit against the Ministry of Health and Welfare and the Health ...

Read more →

Health ministry to reimburse Novartis’ Revolade treating severe aplastic anaemia

 1 August 2019 - Novartis Korea’s Revolade (eltrombopag olamine) will receive reimbursement for treating people with severe aplastic anaemia who ...

Read more →